

Lallemand expands GMP Pharma capabilities with new anaerobic production equipment

10 September 2025 | News

This further step will enable Biome™ to strengthen its leading position in LBP CDMO activities



This further step will enable Biome™ to strengthen its leading position in LBP CDMO activities

Lallemand has acquired a broad range of state-of-the-art equipment to produce drug substances and drug products in anaerobic conditions, reinforcing its GMP Pharma production capabilities for next-generation strains. The acquisition also includes advanced analytical devices, such as additional Q-PCR and MALDI-TOF. This further step will enable Biome™ to strengthen its leading position in LBP CDMO activities.

Stephan Griffoulière, Operations Vice-President, elaborates: "EXPERT'Biome™ will provide a wide range of services at a GMP pharma-accredited site, including drug substance development from 480L to 17,000L in both aerobic and anaerobic conditions; Live Biotherapeutic products manufacturing in sachets, capsules and blisters; and advanced analytical tools, including classical plating technologies and new approaches for multi-strain products such as PMA-PCR, flow cytometry, and MALDI-TOF. This investment, dedicated to the French GMP pharma plant Saint-Simon, positions EXPERT'Biome™ as one of the global leaders in the live biotherapeutics industry."

Laurie Rey, Head of CDMO Business Development at Lallemand Health Solutions, pursues: "These newly acquired cutting-edge technologies, together with the extension of our R&D laboratories by more than 800m², and paired with its in-house Microbiome Program dedicated to developing next-generation probiotics, give Lallemand a competitive edge." The Microbiome Program enables the improvement of methods and skills to accelerate the development of strains and bioprocesses, particularly on strict anaerobes.

Jérôme Panes, President and General Manager at Lallemand Health Solutions, specifies: "With this recent acquisition and ongoing investments in our Saint-Simon plant, EXPERT'Biome™ is well-positioned to support our partners from early development stages through clinical batches to commercial supply in a highly competitive and specialised market. Our expertise, combined with the acquired cutting-edge technologies, makes EXPERT'Biome™ one of the world leaders in the field of LBP and probiotics."